DYNAVAX TECHNOLOGIES CORP (DVAX)
US2681582019 - Common Stock
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Dynavax Technologies (DVAX) Q3 2024 Earnings Call Transcript
DVAX earnings call for the period ending September 30, 2024.
Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a...
Dynavax Announces $200 Million Share Repurchase Program
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Breaks Above 200-Day Moving Average - Bullish for DVAX
Dynavax Adopts Limited-Duration Stockholder Rights Plan
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...
Lantheus Appoints Julie Eastland as New Board Member
Dynavax Technologies (DVAX) Q2 2024 Earnings Call Transcript
DVAX earnings call for the period ending June 30, 2024.
DVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024
DVAX stock results show that Dynavax Technologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
DVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dynavax Technologies (NASDAQ:DVAX) just reported results for the second quarter...
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Dynavax to Present at Upcoming Investor Conferences
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application...
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
DVAX earnings call for the period ending March 31, 2024.
DVAX Stock Earnings: Dynavax Technologies Misses EPS, Misses Revenue for Q1 2024
DVAX stock results show that Dynavax Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
DVAX Stock Earnings: Dynavax Technologies Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dynavax Technologies (NASDAQ:DVAX) just reported results for the first quarter ...
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Dynavax Technologies Enters Oversold Territory (DVAX)
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...
First Week of May 17th Options Trading For Dynavax Technologies (DVAX)
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
DVAX earnings call for the period ending December 31, 2023.
Dynavax GAAP EPS of $0.00 beats by $0.01, revenue of $55.6M beats by $2.87M (NASDAQ:DVAX)
Dynavax reported better-than-expected Q4 earnings with a beat in EPS and revenue.
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
First Week of October 18th Options Trading For Dynavax Technologies (DVAX)
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...
Why Vera Therapeutics Stock Soared by 22% This Week
Executive changes and a bullish analyst take combined to boost sentiment on the company.
3 Stocks Set to Soar 68% to 200% Higher
Analyst stock picks for outsized growth potential mean these companies should handily outperform the market averages.
Dynavax reports 46% Y/Y increase in HEPLISAV-B vaccine net product revenue (NASDAQ:DVAX)
Dynavax Technologies reports strong growth in Q4 2023 with HEPLISAV-B vaccine revenue of $51M, representing a YoY increase of 46%.
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...